Henrik Sorensen Shares of Compugen (CGEN) added ~16% in the premarket on Wednesday after the Israel-based biotech announced an agreement with AstraZeneca (AZN) to monetize a portion of future royalties linked to its cancer drug rilvegostomig. As part of the agreement, the Anglo-Swedish Post navigation Norgine mejora su cartera de productos de hepatología y especialidadesGinkgo Bioworks and Agricen Enter Collaboration to Optimize Manufacturing Processes for a Key Agricultural Soil Amendment
